No Detail Found!

Outcomes of patients with NPM1 positive acute myeloid leukemia, an experience from a tertiary care hospital in Karachi, Pakistan

Author(s)
Maria Zulfiqar Department of Oncology, Aga Khan University Karachi, Pakistan
Natasha Ali Department of Pathology and Laboratory Medicine/ Oncology, Aga Khan University Karachi, Pakistan
Usman Shaikh Department of Pathology and Laboratory Medicine/ Oncology, Aga Khan University Karachi, Pakistan
Hamzah Jehanzeb Medical College, Aga Khan University Karachi, Pakistan
Salman Arif Department of Oncology, Aga Khan University Karachi, Pakistan
Nabiha Saeed Department of Oncology, Aga Khan University Karachi, Pakistan
Zurrya Fasih Khan Department of Oncology, Aga Khan University Karachi, Pakistan
Zeeshan Ansar Department of Pathology and Laboratory Medicine, Aga Khan University Karachi, Pakistan
Abstract
Objectives: To determine the response to induction chemotherapy, overall survival, and relapse rate in patients with NPM1-positive acute myeloid leukaemia. Methodology Patients diagnosed with AML from January 2015 to July 2022 at Aga Khan University Hospital Karachi were included in the study. Patient demographics, clinico-haematological parameters, and molecular analysis for the NPM1 mutation were performed. Response to standard induction chemotherapy, overall survival, and relapse rate were assessed. Results: A total of 76 cases of AML were analysed. The mean age of the sample was 33.7 years, of which 63.2% were males and 36.8% were females. The patients were stratified into two groups: those who were positive for NPM1 while negative for FLT3 (NPM+/FLT3-), representing 18.4%, and those who were negative for both NPM1 and FLT3 (FLT3-/NPM-), representing 81.6% of cases. On day 28 post-induction, the complete remission rate was 78.6% in the NPM1 positive group and 77.4% in the NPM1 negative group. In the NPM1+/FLT3-group, 54.5% of cases who were in remission at day 28 subsequently relapsed, compared to 50.0% of NPM1-/FLT3-cases. The overall survival could not be assessed between both the groups due to the low number of deaths. Conclusion: AML patients harbouring only the NPM1 mutation do not show significant differences in outcome as compared to those negative for both mutations.
Publication Details
Page(s) 84-88
DOI DOI not available
Published Journal: Journal of Haematology and Stem Cell Research, Volume: 3, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Acute myeloid leukemia (AML), FLT-3 ITD, Complete remission (CR), Overall survival (OS), FLT-3TKD and NPM-1., Relapse rate (RR)
0

Citations

0

Downloads

98

Views